<DOC>
	<DOCNO>NCT01937975</DOCNO>
	<brief_summary>Grazoprevir ( MK-5172 ) Elbasvir ( MK-8742 ) study principal component combination oral therapy hepatitis C virus ( HCV ) . The study examine pharmacokinetic ( PK ) profile Grazoprevir Elbasvir follow 10 day dose participant end stage renal disease ( ESRD ) hemodialysis ( HD ) participant severe renal impairment . Both group compare healthy match control .</brief_summary>
	<brief_title>The Pharmacokinetics Grazoprevir ( MK-5172 ) Elbasvir ( MK-8742 ) Participants With Renal Insufficiency ( MK-5172-050 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>All Participants For female childbearing potential : either sexually inactive ( abstinent ) 14 day prior first dose throughout study use acceptable birth control method . Females nonchildbearing potential must undergo sterilization procedure least 6 month prior first dose Nonvasectomized male participant must agree use condom spermicide abstain sexual intercourse trial 90 day stop study medication agree donate sperm time period Participants ESRD HD Maintained stable regimen HD within 3 month prior first dose Participants Severe Renal Impairment Estimated glomerular filtration rate ( eGFR ) screen &lt; 30 mL/min/1.73m^2 Healthy Controls Participant within Â± 10 year mean age within 10 % mean body mass index severe renal impairment participant eGFR screen &gt; =80 mL/min/1.73m^2 All Participants History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological disease whose current condition consider unstable History presence alcoholism drug abuse within past 6 month Female participant pregnant lactate Regular user medication ( include counter ) would significantly alter GFR Donation blood significant blood loss within 56 day prior first dose study medication ( ) Plasma donation within 7 day prior first dose study medication ( ) A renal transplant nephrectomy Participants ESRD Severe Renal Impairment Rapidly fluctuate renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>